NCT07597369

Clinically Actionable Tumor-Associated Antigens in Prostate Cancer

RecruitingOBSERVATIONAL

Trial Details

Start: 2026-01-01Est. Completion: 2029-01-01

Enrollment target: 1,600 participants

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China

Other microbiome trials you might be interested in

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand TherapyPhase 1Recruiting

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8

This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) rad…

Los Angeles, United StatesEst. completion Dec 31, 2026

View Trial →

MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER TrialSUSPENDED

Prostate Carcinoma

This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificia…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.